Farallon Capital Management’s Tango Therapeutics TNGX Stock Holding History

Farallon Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$384M	Buy	12,277,000 +3,179,589	+35%	+$78.6M	1.77%	18
2026 Q1	$190M	Sell	9,097,411 -3,964,000	-30%	-$55.2M	1%	33
2025 Q4	$116M	Buy	13,061,411 +2,304,411	+21%	+$19.9M	0.5%	45
2025 Q3	$90.4M	Buy	10,757,000 +1,600,000	+17%	+$10.8M	0.37%	46
2025 Q2	$46.9M	Buy	9,157,000 +4,546,070	+99%	+$11.2M	0.2%	56
2025 Q1	$6.32M	Buy	4,610,930 +610,930	+15%	+$1.5M	0.03%	78
2024 Q4	$12.4M	Buy	+4,000,000	New	+$18.6M	0.05%	79
2023 Q1	–	Sell	-270,000	Closed	-$1.96M	–	203
2022 Q4	$1.96M	Sell	270,000 -30,000	-10%	-$211K	0.01%	167
2022 Q3	$1.09M	Hold	300,000	–	–	0.01%	214
2022 Q2	$1.36M	Hold	300,000	–	–	0.01%	212
2022 Q1	$2.27M	Hold	300,000	–	–	0.01%	212
2021 Q4	$3.28M	Hold	300,000	–	–	0.02%	199
2021 Q3	$3.88M	Hold	300,000	–	–	0.02%	201
2021 Q2	$3.41M	Buy	+300,000	New	+$3.37M	0.01%	197

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Farallon Capital Management's TNGX Position: Q2 2026 in Review

Farallon Capital Management increased its Tango Therapeutics (TNGX) stake by 35% in Q2 2026, buying an estimated $78.6M and bringing the position to 12,277,000 shares worth $384M. The position accounts for 1.77% of the portfolio, ranked #18.

Farallon Capital Management first reported a position in TNGX in Q2 2021 and has held it in 14 quarters since. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Farallon Capital Management held 12,277,000 shares of Tango Therapeutics worth $384M as of Q2 2026.
Farallon Capital Management bought 3,179,589 Tango Therapeutics shares in Q2 2026, an estimated $78.6M.
Tango Therapeutics made up 1.77% of Farallon Capital Management's portfolio in Q2 2026, its #18 holding.
Farallon Capital Management first reported a position in Tango Therapeutics in Q2 2021 and has held it in 14 quarters since.
247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.